The global generalized anxiety disorder therapeutics market, estimated at US$ 8,869.50 million in 2021, is projected to surpass US$ 12,193 million by 2030, at a revenue CAGR of 3.60%, according to the latest evaluation by Growth Plus Reports. The study analyzes the best impactful strategies, macroeconomic conditions, trends, opportunities, competition, market dynamics, market size, data and projections, and key investment areas.
Key Takeaways:
- The increasing prevalence of mental diseases will drive the demand for generalized anxiety disorder therapeutics during the forecast period.
- Increasing healthcare expenditure will encourage market revenue growth.
- North America will dominate the global market.
Download PDF Brochure of Generalized Anxiety Disorder Therapeutics Market Size – COVID-19 Impact and Global Analysis with Strategic Developments at: https://www.growthplusreports.com/inquiry/request-sample/generalized-anxiety-disorder-therapeutics-market/7905
Generalized Anxiety Disorder Therapeutics Market Scope
|
Report Attribute |
Details |
|
Market size value in 2021 |
US$ 8869.5 million |
|
Revenue forecast in 2030 |
US$ 12193 million |
|
Growth Rate |
CAGR of 3.6% from 2022 to 2030 |
|
Base year for estimation |
2021 |
|
Forecast period |
2022-2030 |
|
Segments covered |
drug class, distribution channel, and region. |
|
Regional scope |
North America, Europe, Asia Pacific, and the Rest of the World (ROW) |
Market Drivers
The growth in anxiety and mental health disorders is the primary factor driving the revenue growth of the global generalized anxiety disorder therapeutics market. Additionally, a positive shift in the dialogue and understanding of mental health and potential drugs in the pipeline for anxiety disorder and generalized anxiety disorder contribute to market revenue growth. Furthermore, government measures aimed at lowering the burden of anxiety disorders and mental diseases, in addition to the rapid commercialization of medicines for anxiety disorders and depression, will support the market’s revenue growth.
Market Segmentation
Growth Plus Reports has analyzed the global generalized anxiety disorder therapeutics market from three perspectives: Drug Class, Distribution Channel, and Region.
Drug Class Segmentation: Based on the drug class, the global generalized anxiety disorder therapeutics market is segmented into antidepressants, azapirones, benzodiazepines, and others. The antidepressants segment dominates the market with the largest revenue share because of the improved effectiveness of the drug in lowering symptoms of anxiety and other mental illnesses.
Distribution Channel Segmentation: Based on the distribution channel, the global generalized anxiety disorder therapeutics market is segmented into hospital pharmacies, retail pharmacies, and online pharmacies. The hospital pharmacy segment dominates the market because of high patient footfall in hospitals for diagnosis and admissions.
Regional Growth Dynamics
Based on the region, the global generalized anxiety disorder therapeutics market is segmented into North America, Europe, Asia Pacific, and the Rest of the World. North America dominates the global generalized anxiety disorder therapeutics market with the largest revenue share. The considerable revenue share of North America in the global generalized anxiety disorder therapeutics market can be attributed to the high prevalence of anxiety and other mental disorders, the presence of key players involved in the production of medicines for the treatment of generalized anxiety disorder, the increased approval and launch of new drugs, and government initiatives to address mental health in this region.
Request for Customization – https://www.growthplusreports.com/inquiry/customization/generalized-anxiety-disorder-therapeutics-market/7905
Competitive Landscape
The following are the top companies in the global generalized anxiety disorder therapeutics market:
- Abbvie Inc.
- Mind Medicine Inc.
- Genentech Inc.
- Pfizer Inc.
- Eli Lilly and Company
- GSK PLC
- VistaGen Therapeutics
- Abbott Laboratories Inc.
- H. Lundbeck A/S
- Merck & Co. Inc.
- Johnson & Johnson
- AstraZeneca
The market for generalized anxiety disorder therapeutics is very competitive and complex. Prominent companies are developing new products and forming strategic alliances to fulfill the growing global demand and maintain a strong market position.
Recent developments:
- Vistagen Therapeutics, Inc. reported in September 2022, after completing an intermediate analysis, that PALISADE-2, the company’s second Phase 3 clinical trial evaluating drug candidate PH94B as an immediate treatment for anxiety in individuals with Social Anxiety Disorder (SAD), is proceeding as planned.
- HMNC Brain Health announced encouraging top-line results from its Phase 2 Proof-of-Concept investigator-initiated study of its oral prolonged-release formulation of ketamine (KET01) in Treatment-Resistant Depression in March 2022. (TRD).
Table of Content
- INTRODUCTION
- Market Ecosystem
- Timeline Under Consideration
- Historical Years – 2020
- Base Year – 2021
- Forecast Years – 2022 to 2030
- Currency Used in the Report
- RESEARCH METHODOLOGY
- Research Approach
- Data Collection Methodology
- Data Sources
- Secondary Sources
- Primary Sources
- Market Estimation Approach
- Bottom Up
- Top Down
- Market Forecasting Model
- Limitations and Assumptions
- PREMIUM INSIGHTS
- Current Market Trends (COVID-19 Perspective)
- Key Players & Competitive Positioning (2021)
- MARKET DYNAMICS
- Drivers
- Restraints/Challenges
- Opportunities
Generalized Anxiety Disorder Therapeutics Market TOC
Buy this Premium Research Report: https://www.growthplusreports.com/checkout-7905
VALUE PROPOSITIONS RELATED TO THE REPORT:
- Powered with Complimentary Analyst Hours and Expert Interviews with Each Report
- Comprehensive quantitative and qualitative insights at segment and sub-segment level
- Covid 19 impact trends and perspective
- Granular insights at global/regional/country level
- Deep-rooted insights on market dynamics (drivers, restraints, opportunities) and business environment
- Blanket coverage on competitive landscape
- Winning imperatives
- Exhaustive coverage on ‘Strategic Developments’ registered by leading players of the market
CUSTOMIZATION OPTIONS:
- Distributor Landscape Assessment
- Pricing Intelligence
- Customer Base Assessment
- Investment & Initiatives Analysis
- ‘Business Profile’ of Key Players
Schedule a call with our analyst: https://appoint.ly/s/salesZ3Jvd3RocGx1c3JlcG9ydHMuY29t/introduction
Visit our report store at – https://www.growthplusreports.com/report-store
Browse related reports:
Invasive Aspergillosis Therapeutics Market by Drug Class (Azoles, Antibiotics), by Route of Administration (Oral, Parenteral) – Global Outlook & Forecast 2022-2030
Kidney Stone Management Market by Type (Calcium Oxide, Calcium Oxalate), Treatment Type (Lithotripsy, Percutaneous Nephrolithotomy), End-user (Hospitals, Ambulatory Surgical Centers, Specialty Clinics) – Global Outlook & Forecast 2022-2030
Medical Illumination Systems Market by Product Type (Surgical Lights, Specialty Light), by Technology (Halogen Lights, LED lights) by End User (Specialty Centers, Hospitals & Clinics) – Global Outlook & Forecast 2022-2030
Mass Spectrometry Market by Product Type (Hybrid, Single), by Application (Pharmaceutical Analysis, Proteomics, Metabolomics), by End-user (Pharmaceutical & Biotechnology, Food & Beverage Testing) Global Outlook & Forecast 2022-2030
Medical Clothing Market by Product (Surgical Drapes, Scrubs & Gowns, Gloves, Facial Protection, Sterilization Wraps), Usage (Disposable, Reusable), End user (Hospitals, Outpatient Facilities, Home Care) – Global Outlook & Forecast 2022-2030
About Us:
Growth Plus Reports is part of GRG Health, a global healthcare knowledge service company. We are proud members of EPhMRA (European Pharmaceutical Marketing Research Association).
Growth Plus portfolio of services draws on our core capabilities of secondary & primary research, market modelling & forecasting, benchmarking, analysis and strategy formulation to help clients create scalable, ground-breaking solutions that prepare them for future growth and success.
We were awarded by the prestigious CEO Magazine as “Most Innovative Healthcare Market Research Company in 2020.
Contact:
Manan Sethi
Director, Market Insights
Email: sales@growthplusreports.com
256 Chapman Road
STE 105-4, Newark,
New Castle – 19702, USA
Phone no: +1 888 550 5009
Web: https://www.growthplusreports.com/